IOL Chemicals and Pharmaceuticals DuPont analysis

Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
0.75×0.75×0.73×0.74×0.74×
0.99×0.98×1.06×1.08×1.05×
9.1%8.1%6.3%7.9%8.1%
0.93×0.93×0.90×1.00×1.11×
1.44×1.44×1.41×1.39×1.34×
8.9%7.9%6.2%8.8%9.3%
7.9%7.9%6.1%8.6%9.6%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

IOLCP₹184.93

IOL Chemicals and Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersMOREPENLABFDCINNOVACAPORCHPHARMASENORESSANOFIGUJTHEMRPGLIFEMcap ₹5,429 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×0.740.740.730.750.75
Interest Burden (Pretax/EBIT) ×1.051.081.060.980.99
EBIT Margin %8.107.866.278.149.06
Asset Turnover ×1.111.000.900.930.93
Financial Leverage (Assets/Equity) ×1.341.391.411.441.44
ROE (5-step product, year-end total equity) %9.348.786.177.948.91
ROE (owners' profit / average owners' equity) %9.608.626.137.907.90
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.